Skip to main content

Table 3 Association between diagnosis period and type of initial treatment

From: Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study

  Not yet treated BCS Mx with IBR Mx without IBR Chemotherapy Hormonal treatment Other
DCISa        
 Weeks 2–8 2.04 (1.44–2.88) 0.81 (0.63–1.04) 0.87 (0.58–1.32) 0.95 (0.66–1.36) 0.71 (0.08–6.32) 0.27 (0.03–2.19) NA
 Weeks 9–11 2.18 (1.31–3.61) 0.72 (0.49–1.05) 0.56 (0.28–1.10) 1.36 (0.82–2.26) NA 2.13 (0.40–11.33) NA
 Weeks 12–13 1.38 (0.61–3.13) 0.80 (0.47–1.36) 0.44 (0.15–1.29) 1.38 (0.70–2.72) NA 18.32 (3.68–91.30) NA
 Weeks 14–17 1.07 (0.37–3.11) 0.53 (0.28–1.04) 1.92 (0.78–4.74) 1.40 (0.60–3.25) 5.98 (0.57–62.65) 2.13 (0.22–20.53) NA
Invasiveb        
 Weeks 2–8 1.11 (0.84–1.48) 0.93 (0.83–1.04) 0.93 (0.74–1.16) 1.01 (0.88–1.16) 0.96 (0.82–1.12) 1.23 (1.05–1.44) 0.50 (0.25–0.98)
 Weeks 9–11 0.95 (0.60–1.50) 0.93 (0.79–1.10) 0.97 (0.70–1.36) 1.11 (0.91–1.36) 0.59 (0.45–0.76) 1.92 (1.53–2.41) NA
 Weeks 12–13 0.63 (0.27–1.45) 0.91 (0.70–1.17) 0.52 (0.28–0.96) 0.90 (0.65–1.24) 0.66 (0.45–0.95) 3.01 (2.20–4.11) NA
 Weeks 14–17 0.83 (0.48–1.45) 0.75 (0.61–0.92) 1.08 (0.73–1.59) 1.11 (0.87–1.41) 1.31 (1.01–1.70) 1.26 (0.96–1.65) 0.42 (0.13–1.38)
  1. Logistic regression calculating the odds ratios and 95% confidence intervals to investigate the association between period of diagnosis of the tumor (week 2–17 2018/2019 as a reference) and type of initial treatment, for DCIS and invasive tumors separately
  2. BCS, breast conserving surgery; DCIS, ductal carcinoma in situ; IBR, immediate breast reconstruction; Mx, mastectomy; NA, not applicable
  3. aOdds ratios are adjusted for age groups, socioeconomic status, and region
  4. bOdds ratios are adjusted for age groups, socioeconomic status, stage, subtype, and region